Decreased striatal dopamine-receptor binding in sporadic ALS: glutamate hyperactivity?
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 10214758.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The pathogenesis of ALS may be related to increased glutamatergic excitotoxicity. The striatum receives massive glutamatergic input. Animal studies suggest that glutamate decreases striatal D2-receptor synthesis. In drug-naive, sporadic ALS patients we demonstrated decreased striatal D2-receptor binding in vivo that could be partially reversed by the glutamatergic transmission blocker riluzole. Our findings support the glutamatergic excitotoxicity hypothesis in sporadic ALS.
Medical subject headings
- Amyotrophic Lateral Sclerosis
- Corpus Striatum
- Receptors, Dopamine D2
- Riluzole